Haemonetics Q1 FY27: Revenue +5.6% to $339.4M, net income -3% to $33.0M on higher tax rate

Filed August 6, 2026 · Period ending June 27, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read

Key Changes

• high

  Net income fell 3.0% to $33.0M despite revenue and operating income growth, as the effective tax rate jumped to 30.6% from 24.7% due to $1.7M of discrete tax expense (stock compensation shortfalls and valuation allowance impacts on acquired-entity losses).

  MD&A: Tax Rate verify on EDGAR →
• high

  Apheresis revenue (formerly Plasma) turned positive at +5.3% after a 4.4% decline in the prior year, driven by volume growth and share gains as the CSL Plasma customer transition headwind has passed.

  MD&A: Apheresis Revenue verify on EDGAR →
• high

  Operating cash flow improved $34.9M YoY to $52.3M, driven by lower working-capital outflows ($20M vs $55.5M in the prior year).

  MD&A: Operating Cash Flow verify on EDGAR →